Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

py with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

Poniard Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues $- $- $- $-

Operating expenses:

Research and development 9,024 5,050 24,511 16,362

General and administrative 3,383 2,806 11,289 8,584

Total operating expenses 12,407 7,856 35,800 24,946

Loss from operations (12,407) (7,856) (35,800) (24,946)

Other income, net 170 897 1,177 1,730

Net loss (12,237) (6,959) (34,623) (23,216)

Preferred stock dividends (125) (125) (375) (375)

Net loss applicable to common

shares $(12,362) $(7,084) $(34,998) $(23,591)

Los
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Turks and Caicos Islands, BWI (PRWEB) May 02, 2015 ... a new website! It is http://www.thevenetiangracebay.com , ... itself, and it incorporates the stunning white and attractive ... to a study of Google, sixty seven percent of ... The study showed that smartphones were used in ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... 2015 The Workgroup for Electronic ... on the use of health IT to create efficiencies ... resource to the United States Government Accountability Office (GAO) ... cards in Medicare. The report, “ Potential Uses of ... released to the public on Apr. 24, 2015 and ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in both ... for telemedicine. , “Such action is unprecedented in ... said Jonathan Linkous, CEO of the American Telemedicine Association (ATA). ... embrace the use of telecommunications in the delivery of care. ... to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... This release is available in Spanish . ... the same area as the original tumour remains the strongest, ... patients who have been free of disease for a very ... seventh European Breast Cancer Conference (EBCC7). Dr Sven Mieog, ...
... Milan, Italy, 24 March 2010 - Despite the aches and ... a positive outlook, remembering the positive experiences from their past. ... of Elsevier,s Cortex ( http://www.elsevier.com/locate/cortex ), reveals that ... lens is linked to the way in which the brain ...
... ... normal guides on how to assemble a hookah, a free video series demonstrating the ... ... go-to for information, TheHookahMonster.com’s marketing director, Mario Ferazzano, has decided to offer a free ...
... is best way to prevent breast cancer deaths , WEDNESDAY, ... does not appear to increase overall survival from the disease, ... instead be due to controlling risk factors and improved treatments, ... as we hoped years ago," said study author Dr. Karsten ...
... A ... Provo, ... 90 program--a new 90 day risk-free offer in the United States to try Tahitian Noni ... the appropriate amount of product for 90 days, then they can get their full purchase price ...
... ... Turn Back the Clock with a Proven, Personalized, Anti-Aging Program". Dr. Karlis Ullis shares how ... www.AskAnAntiAgingExpert.com . , ... March 24, 2010 -- What do the Today show, Hard Copy, Dateline NBC, and Sally ...
Cached Medicine News:Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Older adults remember the good times 2Health News:TheHookahMonster.com Offers Free Shisha Tobacco Education 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 3Health News:Noni For 90 Offer Made By Tahitian Noni International 2Health News:Free Anti-Aging Teleseminar Teaches People Key Lifestyle Changes To Maximize Longevity 2
(Date:4/30/2015)... April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the fiscal year ... herein are in Canadian dollars unless otherwise stated. ... significant, with the right strategic partners and additional ...
(Date:4/30/2015)... , April 30, 2015  IRIDEX Corporation (NASDAQ: ... first quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, May 7, 2015 ... other business developments. Interested parties may access ...
(Date:4/30/2015)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) announced today ... after the market closes on Thursday, May 7, 2015.  ... held on Thursday, May 7, 2015, at 4:30 p.m. ... participate in the call, please dial 877-303-1298 (for U.S. ... the teleconference will be available for one week and ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results 2
... FOREST, Ill., March 9, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... and Hospira expects to launch the product later this month. ... a variety of cancers. In 2010, U.S. sales of Taxotere ...
... Tris Pharma, a specialty pharmaceutical company that develops ... US Food and Drug Administration (FDA) has accepted ... the treatment of allergies in kids two years ... Suspension will provide an alternative to the currently ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Generic Docetaxel 2Tris Announces NDA Acceptance of Extended Release Carbinoxamine Oral Suspension for the Treatment of Allergies in Kids Two Years and Older 2
Cushing Flat Drill, only Component Parts and Accessories for HUDSON Cranial Drill. 14 mm...
Hudson brace only. Component parts and accessories for Hudson cranial drill....
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Length-9 (229 mm) Tapered retractor blades....
Medicine Products: